| The firm has introduced the antibiotics brands Trixone, Qubid and Flaag in the anti-infective range and Bonforte for patients suffering from osteoporosis in the orthocare range, in the state and is in talks with clients. |
| Talking to Business Standard, KK Puri, director, Flamingo Pharmaceuticals, said: "In the first phase, we are eyeing the market for anti-infectives, and expect to capture at least a 1 per cent share in the first year. We have received approval to hold clinical trials for our drugs at Aligarh Muslim University and King George Medical University, the results of which will help us to penetrate in the market further." |
| The annual retail drug market in the state stands at Rs 1,500 crore, of which the share of anti-infectives is Rs 750 crore. |
| "The domestic pharmaceutical market is estimated to be worth Rs 27,000 crore in India. As one of the largest consumers of pharmaceuticals, Uttar Pradesh is a very important market for Flamingo. We will target both the individual and institutional customers in the state and plan to have more than 100 distributors, 60 medical representatives and 12 managers in Uttar Pradesh in the first phase," Puri said. |
| Rs 120 crore Flamingo Pharmaceuticals has exported for over 20 years and began domestic operations in India about six months ago. |
| The company is targeting sales of Rs 500 crore over the next three years. For its Indian domestic market, the company plans to have a field force of 2,500 and more than 1000 distributors. The company also plans to enter chronic therapy areas in near future. |
| "For the second phase of operations, we plan to step into formulations for chronic therapies, including diabetes and cardio vascular treatments by end of this year," Puri said. |
Top Section
Explore Business Standard